To require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks, and for other purposes., changes federal law or congressional policy affecting federal agencies and legislative administrators. The main policy domain is Government Operations, Healthcare, Trade.
Who Benefits and How
federal agencies and legislative administrators may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section S1: 1. Short title This Act may be cited as the Pharmaceutical Supply Chain Risk Assessment Act of 2023.
- Section id50f35feb280a49089a188d57b1d5dcb8: 2. Risk assessment The Secretary of Health and Human Services shall lead, in coordination with the Secretary of Defense, the Secretary of Homeland Security,...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks, and for other purposes., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Key Policy Areas
Government Operations, Healthcare, Trade
Primary Purpose
This bill, To require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks, and for other purposes., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Policy Domains
Whole bill
Identified Gains
- federal agencies and legislative administrators
Identified Costs
- federal implementing agencies
Sponsors
Gary C. Peters
D-MI | Primary Sponsor
Legislative Progress
IntroducedMr. Peters (for himself and Ms. Ernst) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary_of_defense"
- → Secretary of Defense
- "secretary_of_homeland_security"
- → Secretary of Homeland Security
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology